News · 18 November 2026

Eli Lilly raises its sales forecast as Zepbound and Mounjaro soar

18 November 2026 · Business · US · Health

Eli Lilly raises its sales forecast as Zepbound and Mounjaro soar
Picture: BioPharma Dive · BioPharma Dive lead image · unknown

Eli Lilly beat Wall Street forecasts on Thursday and raised its sales outlook for the year. It now expects $91 billion to $92 billion in revenue. Its diabetes drug Mounjaro brought in $10.7 billion in the quarter. Its weight loss drug Zepbound added $5.4 billion. Sales of its new obesity pill Foundayo fell short of expectations.

Where this came from. 2 outlets reported this. We read them, then wrote the sixty words above.

Also on 18 November 2026